Russell Investments Group Ltd. Has $106.32 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Russell Investments Group Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 121,030 shares of the biopharmaceutical company’s stock after selling 5,171 shares during the period. Russell Investments Group Ltd. owned 0.11% of Regeneron Pharmaceuticals worth $106,318,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Fortitude Family Office LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. MCF Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the last quarter. Criterion Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Sutton Wealth Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,325,338. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on REGN. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $977.77.

Regeneron Pharmaceuticals Trading Down 0.8 %

Shares of REGN stock traded down $7.48 during trading hours on Friday, hitting $883.20. 505,652 shares of the company were exchanged, compared to its average volume of 431,865. The company has a 50 day simple moving average of $948.00 and a two-hundred day simple moving average of $894.04. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The firm has a market cap of $96.94 billion, a P/E ratio of 25.42, a P/E/G ratio of 2.54 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $10.96 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.